Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tricyclic antidepressive agents].

D Ginestet

    Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Tricyclic antidepressants remain effective for major depression, achieving 60-75% success rates. Research focuses on reducing side effects by developing agents without anticholinergic activity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Psychometric qualities of the French version of the Heinrichs quality of life rating scale.

    European psychiatry : the journal of the Association of European Psychiatrists·2000
    Same author

    [Re-evaluating neuroleptics: their antipsychotic properties?].

    Presse medicale (Paris, France : 1983)·1999
    Same author

    Efficacy of tianeptine in major depressive disorders with or without melancholia.

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·1997
    Same author

    Comorbidity of personality disorders and unipolar major depression: a review.

    Journal of affective disorders·1996
    Same author

    [Comorbidity in a sample of hospitalized depressed patients].

    L'Encephale·1996
    Same author

    [Drugs diverted from reaching drug addicts].

    La Revue du praticien·1995
    Same journal

    Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same journal

    Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same journal

    Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same journal

    CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same journal

    Corrigendum to "Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells" [Biomed. Pharmacother. 189 (2025) 118279].

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same journal

    Corrigendum: "Zebrafish as a model to study inflammation: A tool for drug discovery" [Biomed. Pharmacother. 144 (2021) 112310].

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Neuroscience

    Context:

    • Tricyclic antidepressants (TCAs) are established treatments for major depressive disorder.
    • High efficacy rates (60-75%) are observed, particularly in melancholic depressions.
    • Standard treatment protocols involve initial and extended maintenance phases (3-4 months).

    Purpose:

    • To review the established efficacy and treatment protocols of tricyclic antidepressants.
    • To highlight ongoing research into novel tricyclic agents with improved side-effect profiles.

    Summary:

    • Tricyclic antidepressants are the preferred treatment for major depression due to their proven effectiveness.
    • Treatment duration requires a minimum of one month initially, followed by three to four months of maintenance therapy.

    Related Experiment Videos

  • A significant drawback of TCAs is their anticholinergic activity, prompting research into safer alternatives.

    • Impact:

    • TCAs continue to be a cornerstone in managing severe depression.
    • Understanding TCA treatment duration is crucial for patient recovery.
    • Future developments aim to enhance TCA therapy by minimizing adverse effects, improving patient compliance and outcomes.